2C-T-22
2C-T-22, also known as 4--2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and 2C-T-x families. It is closely related to 2C-T-21 analogue and 2C-T-21.5.
2C-T-22 was briefly described by Alexander Shulgin in his book PiHKAL in the 2C-T-21 entry, but Shulgin only partially completed the chemical synthesis of 2C-T-22 and did not test it. Subsequently, Daniel Trachsel completed the synthesis of 2C-T-22 and defined its dose as greater than 10mg orally and its duration as approximately 6hours. A total dose of 5mg plus 5mg plus 6mg produced the first signs of effects, but higher doses were not explored. Hence, its precise dose range remains unknown.
Pharmacology
Pharmacodynamics
2C-T-22 shows affinity for the serotonin 5-HT2A receptor and the serotonin 5-HT2C receptor. It has been found to be a potent partial agonist of the serotonin 5-HT2A and 5-HT2B receptors. Other receptor and target interactions have also been described.
History
2C-T-22 was first described in the scientific literature by Shulgin in his book PiHKAL in 1991. Subsequently, Trachsel described and completed the synthesis of 2C-T-22 in 2003 and he and his colleagues defined its properties in humans in 2013.
Canada
2C-T-22 is a controlled substance in Canada under phenethylamine blanket-ban language.